Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients a review of clinical effectiveness, cost-effectiveness, and guidelines
There was no primary evidence regarding the clinical effectiveness or cost-effectiveness of immune checkpoint inhibitors for brentuximab vedotin-naïve adults with relapsed or refractory classical Hodgkin lymphoma, irrespective of eligibility for or prior history of autologous stem cell transplantat...
Main Authors: | , , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
June 21, 2019, 2019
|
Edition: | Version 1.0 |
Series: | CADTH rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | There was no primary evidence regarding the clinical effectiveness or cost-effectiveness of immune checkpoint inhibitors for brentuximab vedotin-naïve adults with relapsed or refractory classical Hodgkin lymphoma, irrespective of eligibility for or prior history of autologous stem cell transplantation |
---|---|
Physical Description: | 1 PDF file (16 pages) illustration |